Myocardial Infarction (HORIZONS-AMI) trial, implantation of paclitaxel-eluting stents (PES) safely reduced the rates of ischemic target lesion revascularization (TLR) compared with bare metal stents (BMS) in patients with ST-segment-elevation myocardial infarction (STEMI) undergoing primary percutaneous intervention. Diabetes mellitus is a known predictor of adverse outcomes after percutaneous intervention in STEMI. We therefore sought to assess the impact of PES in diabetic patients with STEMI from the HORIZONS-AMI trial. Methods and Results-A total of 478 patients with diabetes and 2527 without diabetes were randomly assigned to receive PES versus BMS. 
D rug-eluting stents (DES), compared with bare metal stents (BMS), safely reduce restenosis in noncomplex patient populations. 1, 2 However, percutaneous coronary intervention (PCI) with either BMS or DES in high-risk and complex patients is associated with increased rates of adverse outcomes compared with less complex settings. 3, 4 Specifically, patients with diabetes have increased rates of mortality, myocardial infarction, and restenosis compared with nondiabetic patients after elective PCI. 5, 6 Rates of mortality, reinfarction, and stent thrombosis are also increased after primary PCI in patients with evolving ST-segment-elevation myocardial infarction (STEMI). In this regard, paclitaxel-eluting stents (PES), compared with BMS, have been shown to safely reduce recurrent ischemia necessitating repeat revasculariza-tion procedures in both patients with diabetes 1 and patients with STEMI. 7, 8 Subgroup data from modest-sized, randomized trials suggest that PES, compared with BMS, may reduce revascularization in diabetic patients undergoing primary stenting for STEMI without increasing death or reinfarction. 9 However, no published large-scale, randomized trial has specifically examined the relative safety and efficacy of PES in diabetic patients presenting with STEMI.
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HORIZONS-AMI (Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction) was a large-scale, randomized, multicenter trial that compared PES versus BMS implantation in 3006 patients presenting with STEMI. At 1 year, PES compared with BMS significantly reduced the rates of ischemia-driven target lesion revascularization (TLR), with similar rates of death, reinfarction, and stent thrombosis. 8 The present prespecified analysis from HORIZONS-AMI was therefore performed to assess the impact of diabetes mellitus on clinical and angiographic outcomes in patients with STEMI treated with either PES or BMS.
Methods

Study Design
The design and primary outcomes of the HORIZONS-AMI trial have been previously reported. 8,10 -12 Briefly, HORIZONS-AMI was a prospective, multicenter trial in which patients with STEMI undergoing primary PCI were randomly assigned in 2 phases to compare (1) bivalirudin alone plus provisional use of glycoprotein IIb/IIIa inhibitors versus unfractionated heparin plus routine glycoprotein IIb/IIIa inhibitors and (2) the paclitaxel-eluting TAXUS Express 2 stent versus an otherwise identical bare metal Express 2 stent (both Boston Scientific, Natick, MA). Consecutive patients presenting within 12 hours of symptom onset with STEMI (Ն1 mm of ST-segment elevation in Ն2 contiguous leads, new left bundlebranch block, or true posterior MI) were considered for enrollment.
Clinical exclusion criteria were few but included contraindications to study medication (including thienopyridines) or conditions that increase the risk of hemorrhage. 11, 12 After pharmacological randomization, emergent angiography was performed followed by assessment for eligibility in the stent randomized phase of the trial. Lesions with reference vessel diameter 2.25 mm to 4.0 mm and length Ͻ100 mm were eligible. As previously described, left main lesions, bifurcation lesions requiring planned dual stenting, and those with excessive tortuosity or severe calcification were excluded. Patients with multiple lesions and vessels requiring intervention were recruited if all lesions met the study inclusion criteria. Random assignment was stratified by (1) the first random assignment (pharmacology assignment); (2) diabetes mellitus; (3) lesion length Ͼ26 mm (requiring overlapping stents); and (4) United States versus non-United States study site. Eligible patients were assigned in a 3:1 ratio to PES or BMS. 8, 12 Aspirin and a clopidogrel loading dose (300 mg or 600 mg at operator discretion) were administered before catheterization. Standard stent implantation techniques were performed as previously described. 8, 12 Clopidogrel was required per protocol for 6 months after the index procedure (12 months or longer recommended). Complete end point definitions have been reported. 12 A blinded independent clinical events committee adjudicated all primary end point events using original source documents. Angiographic analysis was performed by a core laboratory by technicians blinded to stent assignment using standard criteria. 13 Clinical follow-up was scheduled at 30 days, 6 months, and 1 year. Angiographic follow-up in a subset of 1800 patients was scheduled at 13 months, 1 month beyond the primary 12-month clinical end point.
Statistical Methods
The HORIZONS-AMI trial was powered to show superiority of PES versus BMS for the 12-month primary efficacy end point of TLR and the major secondary end point of angiographic binary restenosis, and noninferiority of PES versus BMS for the composite safety end point of death, reinfarction, stroke, or stent thrombosis. For the present analysis the 1-year clinical and 13-month angiographic outcomes were assessed according to the presence or absence of medically treated diabetes mellitus, and whether or not insulin treatment was required.
Data are summarized using descriptive statistics, presented as proportions (percent, count/sample size), median [first, third quartiles], or meanϮSD. Continuous variables were compared by means of the Wilcoxon rank-sum text or t tests; differences in categorical variables were assessed by 2 or Fisher exact test. All analyses were by intention to treat. Time-to-event data (with data censored at the time of a patient's withdrawal from the study or at the last follow-up visit) are shown as Kaplan-Meier curves and compared with the log-rank test. Relative risks between the groups for time-to-event data are expressed as hazard ratios (HR) with 95% confidence intervals (CI), and as relative rates (RR) with 95% CIs for categorical groups. All analyses were performed using SAS version 9.1.
The institutional review board at each participating center approved the protocol, and all patients provided written informed consent.
Results
Patients
A total of 3006 patients with STEMI were randomly assigned to receive PES or BMS, including 478 patients (15.9%) with diabetes (364 randomly assigned to PES and 114 randomly assigned to BMS) and 2527 patients (84.1%) without diabetes (1892 randomly assigned to PES and 635 randomly assigned to BMS; Figure 1 ). Diabetic status was unavailable in 1 patient. Among the 478 diabetic patients, 129 (27.0%) were treated with insulin (98 randomly assigned to PES and 31 randomly assigned to BMS).
Baseline Features and Medication Use
Concomitant comorbid risk factors were more frequent in patients with compared with those without diabetes, including advanced age, female sex, obesity, hypertension, hyperlipidemia, peripheral vascular disease, prior MI, PCI, and CABG, with presentation more commonly in congestive heart failure and with reduced left ventricular ejection fraction (Table 1) . Diabetic patients were less likely to be current smokers but were less likely to have TIMI flow 0/1 of the infarct artery, and the baseline reference vessel diameter of the infarct lesion was slightly smaller and the minimal lumen diameter was slightly larger than in nondiabetic patients. There were no significant differences in baseline clinical or angiographic characteristics between the randomized PES and BMS groups in either the diabetic or nondiabetic cohorts (data not shown), with the sole exceptions of a slightly lower incidence of prior chronic heart failure in PES-treated versus BMS-treated diabetic Procedural use of unfractionated heparin, GP IIb/IIIa inhibitors, and bivalirudin were balanced between the PES and BMS arms in both diabetic and nondiabetic patients (as expected as a consequence of the randomized design and stratification for diabetes; Table 2 ). Discharge medication use was also well matched between the PES and BMS arms, in both diabetic and nondiabetic patients. The rate of aspirin use was slightly higher in the nondiabetic compared with diabetic patient group at 30 days (98.7% versus 96.9%, Pϭ0.004) but was not significantly different at 6 or 12 months. Thienopyridine use at 12 months was slightly less common in diabetic versus nondiabetic patients (66.9% versus 71.6%, Pϭ0.05) and was significantly lower in BMS-treated compared with PES-treated patients in the nondiabetic subgroup at 6 and 12 months (Table 2) .
Clinical Outcomes in Diabetic and Nondiabetic Patients
Pooled across stent types, the 12-month composite rates of death, reinfarction, stroke, or ischemia-driven TVR were significantly higher in diabetic compared with nondiabetic patients (14.8% versus 10.3%, Pϭ0.003), driven by statistically significant increases in all-cause mortality (6.3% versus 3.0%, PϽ0.001) and stroke (2.0% versus 0.8%, Pϭ0.02), with a trend present for greater TVR (Pϭ0.08, Table 3 ).
As shown in Table 3 and (Figure 2A) , ischemic TLR to 12 months was similar in nondiabetic (4.3%) and non-insulin-treated diabetic patients (4.4%) but somewhat higher in insulin-treated diabetic patients (7.3%). In contrast, BMS-treated patients demonstrated a greater progressive increase in ischemic TLR rates between diabetic and nondiabetic patients ( Figure 2B ).
There were no significant differences between the BMSand PES-treated diabetic or nondiabetic patients in 12-month safety outcomes, including death, reinfarction, stroke, or stent thrombosis (Tables 3 and 4 ). Stent thrombosis rates (academic research consortium definite or probable) were high with both stent types in insulin-treated diabetic patients (8.3% PES, 13.3% BMS), however, compared with rates in noninsulin-treated diabetic patients (1.2% PES, 1.2% BMS).
Angiographic Outcomes in Diabetic and Nondiabetic Patients
In-stent and analysis segment late loss and restenosis rates at 13 months were significantly lower in PES-treated compared with BMS-treated diabetic patients with STEMI ( Figure 3A and 3B). Comparable findings were present in patients without diabetes, although the absolute magnitude of reduction in late loss and restenosis with PES compared with BMS were less than in diabetic patients ( Figure 3C and 3D) .
Discussion
In the HORIZONS-AMI trial, stent randomization was stratified by the presence of diabetes. As such, with 478 diabetic patients enrolled, the present report represents the largest randomized, controlled trial to date in diabetic patients with STEMI. PES compared with BMS in diabetic patients resulted in a statistically significant 55% relative reduction (6.0% absolute reduction) in ischemia-driven TLR at 12 months and a significant 81% relative reduction (35.7% absolute reduction) in binary in-stent restenosis at 13 months. The relative risk reduction for 12-month TLR with PES versus BMS was even greater in insulin-treated diabetic patients (65% relative risk reduction, 14.1% absolute reduction; Pϭ0.046). In contrast, nondiabetic patients had a 37% relative reduction (2.5% absolute reduction) in TLR at 12 months with PES. Thus, the relative and absolute benefits of PES compared with BMS in patients with STEMI are especially evident in high-risk patients with diabetes. In the present study, the 12-month rates of ischemic TLR were 6.8% and 11.2% in nondiabetic and diabetic patients, respectively, treated with BMS, consistent with the higher rates of TLR seen in diabetic patients without STEMI after BMS in prior studies. 14 In contrast, PES treatment resulted in comparable 12-month ischemic TLR rates in nondiabetic (4.3%) and diabetic patients (5.2%) presenting with STEMI, suggesting that PES can mitigate the increased restenosis risk imparted by diabetes, as previously reported for PES in patients without STEMI. 15, 16 These results suggest that paclitaxel may act independent of signaling pathways affected by diabetes. 17 The results of the HORIZONS-AMI diabetes subanalysis are consistent with prior smaller studies. In a prior review, 9 reintervention rates in PES-treated diabetic STEMI patients of 5.9% (1/17) from the HAAMI-STENT trial (mean followup, 16.7 months) 18 and 6.5% (2/31) from the PASSION trial (at 12 months) were reported. 19 From the same publication, reintervention with sirolimus-eluting stents in diabetic patients with STEMI was required in 7.1% (2/28) of patients in SESAMI (at 12.3 months), 20 13 .3% (2/15) in STRATEGY (at 24.2 months), 21 and 7.3% (4/55) in TYPHOON (at 12.1 months). 22, 23 Large-scale comparative randomized trials are required to determine whether the angiographic and clinical results with PES versus sirolimus-eluting stents (or other DES) are significantly different.
In recent years, there has been considerable concern over the potential for increased stent thrombosis rates with DES compared with BMS. 24 Stent thrombosis is a particular concern for STEMI patients when DES are implanted in ruptured plaques with a large necrotic core (the lesion substrate responsible for most cases of STEMI). 25 Diabetes is also a known correlate of stent thrombosis, 26,27 presenting an In accordance with the well-known concurrence of comorbid risk factors in patients with diabetes, 28 the 1-year rate of mortality was significantly higher in diabetic compared with nondiabetic patients, driven by an increase in cardiac death. However, there were no significant differences in mortality between PES and BMS in either diabetic or nondiabetic patients at the end of 1-year, and the relative increase in mortality between diabetic and nondiabetic patients was similar across treatment arms. These findings are consistent with other studies. 6,29 -31 Several limitations of the current study should be considered. First, as expected, numerous baseline imbalances between diabetic and nondiabetic patients were present. However, baseline factors were well matched between the randomized PES and BMS treatments groups, and stratification for diabetes ensured that each treatment arm contained a similar percentage of diabetic patients. Second, although the comparable adverse cardiovascular event and stent thrombosis rates in the PES group compared with the BMS group (even in high-risk insulin-treated diabetic patients) suggest that PES is safe in STEMI patients with diabetes at 1 year, longer-term follow-up is needed to fully characterize the long-term safety profile of PES in diabetic patients with STEMI, especially as regards very late stent thrombosis. Third, although the HORIZONS-AMI study had relatively few exclusion criteria, the results may not apply to patients not studied (eg, left main and bifurcation lesions requiring 2 stents, lesions requiring stent length Ͼ100 mm, and lesions with excessive tortuosity or severe calcification). Although not formally excluded, few patients were enrolled with cardiogenic shock or vein graft occlusion. Fourth, a lesionbased analysis was used for angiographic comparisons, without correction for possible correlated data. Fifth, the present study is underpowered for the subgroups examined; several of the subgroup probability values are nominally significant; and adjustment for multiple testing was not performed. As such, the results from the present analysis should be considered exploratory and hypothesis generating, although interaction testing suggests that the beneficial effect of PES compared with BMS in reducing the 12-month rate of TLR applies to both diabetic and nondiabetic patients. Finally, these results apply only to PES and may not be indicative of outcomes after implantation of other DES, especially given studies that suggest paclitaxel may perform differently than other antiproliferative agents in patients with diabetes. 32, 33 In conclusion, patients with STEMI and diabetes mellitus represent a high-risk group (especially those requiring insulin), with increased rates of restenosis and death at 1 year compared with patients without diabetes. In diabetic patients with STEMI, PES safely reduced the 1-year rates of clinical and angiographic restenosis, improving event-free survival without any apparent safety concerns.
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